American pharmaceutical giant Lilly announced on the 17th that it plans to invest $2.5 billion to build a high-tech production base in Alcai, Rhineland Pfalz, Germany. The company also plans to invest $100 million in the entrepreneurial ecosystem of Germany's life sciences and biotechnology industries.
It is reported that the production base will use state-of-the-art technologies such as automation technology and high-speed production lines to produce drugs. Lilly hopes to leverage this production base to expand its global production network of injectable drugs and related injection aids. Staff from the German pharmaceutical industry will play an important role in strengthening the supply of glucagon drugs to Lilly with their rich experience.
It is understood that the production base is planned to start construction in 2024 and be put into operation in 2027. At that time, approximately 1000 professionals will be employed.
German Federal Minister for Economy and Climate Protection, Robert Habeck, stated that this production base will make significant contributions to the value-added of German industry by introducing high-tech production equipment and research and development. German Federal Minister of Health Karl Lauterbach announced that the government will further improve the research and production environment to ensure that patients can quickly access new treatment options.
The German Federal Agency for Foreign Trade and Investment (GTAI) provided support for Lilly's site selection. Robert Hermann, the general manager of the agency, said that this investment once again proves Germany's attractiveness and strengthens its position as a pharmaceutical center. A highly innovative multinational company has invested in Germany and created high-quality jobs, benefiting both Germany and Europe from the products produced here
According to German media reports, Lilly is one of the world's largest pharmaceutical companies, with operations in Germany since 1960. The company stated that its new factory in Alcai will become its sixth production base in Europe.